AOD-9604: Does the 'Fat-Burning' Peptide Actually Burn Fat?

In a world suddenly obsessed with weight-loss injections, AOD-9604 has a tempting pitch: the fat-burning power of growth hormone, without growth hormone's downsides — no effect on height, muscle or blood sugar, just targeted fat loss. It sounds almost too neat. And the honest verdict is that it more or less is: the mechanism is real and the mouse data are encouraging, but when AOD-9604 was actually tested in people, it didn't deliver. Here's the full story.

What is AOD-9604?

AOD-9604 is a small fragment of human growth hormone — specifically the tail end, amino acids 176 to 191. Researchers noticed that this particular piece of the hormone seemed to carry growth hormone's fat-breakdown (lipolytic) effect while leaving out the parts responsible for growth and blood-sugar changes ². So the design goal was elegant: keep the fat-burning, drop the side effects.

It's a genuinely clever idea, and it's why AOD-9604 was developed as a serious obesity-drug candidate rather than just a gym supplement. As always, though, a clever design is a starting point, not a result — and this is a case where the results are the whole story.

What does the evidence show?

This one has an unusually clear arc, because AOD-9604 was actually taken into human trials — and that's where the gap appears.

In mice, it looked promising. Obese mice treated with this growth-hormone fragment showed increased fat oxidation and reduced weight gain ¹. Exactly the kind of result that justifies moving a compound toward human testing.

In humans, it disappointed. In a 12-week clinical trial in people with obesity, AOD-9604 produced only a small weight change — and, tellingly, no dose-response (higher doses didn't work better, which is a red flag that the effect may not be real) ²³. The development programme was ultimately judged not commercially viable as an obesity treatment. In plain terms: it failed to prove itself where it counted.

How does it compare to the drugs that actually work?

This is worth being blunt about. We're living through a genuine revolution in weight-loss medicine — the GLP-1 drugs and newer agents like retatrutide produce large, well-documented weight loss in proper trials. Against that backdrop, AOD-9604's weak human data look even weaker. If your goal is fat loss, the contrast isn't subtle: one category has transformed the field on the strength of real evidence; AOD-9604 didn't clear the bar.

The approval and sourcing problem

AOD-9604 is not an approved weight-loss medicine. (It has, in some places, been looked at as a food/supplement ingredient — which is a regulatory category about safety as an additive, not proof that it makes you lose weight.) What's sold online for fat loss is an unregulated "research" peptide, with the usual unknown purity, dose and sterility we flag across the peptide category.

What we see at the clinic

AOD-9604 tends to come up with people who want the benefits of the weight-loss-drug era but are wary of the GLP-1 medications and hope a "gentle fat-burning peptide" is a softer option. We're honest: the idea is clever, but it was tested and it underperformed, which is exactly the information the marketing leaves out. Sustainable fat loss comes from proven approaches — nutrition, activity, sleep, and where appropriate the genuinely effective medications used under supervision — not from a peptide that failed its own trials.

Common questions

Does AOD-9604 burn fat? It increased fat breakdown in mice ¹, but in a human obesity trial it produced only a small weight change with no dose-response ² — weak evidence that it meaningfully burns fat in people.

Is it a safer alternative to GLP-1 drugs? "Safer" is the wrong frame when it doesn't clearly work. The GLP-1 drugs have strong evidence; AOD-9604 doesn't.

Is it approved? Not as a weight-loss medicine. Any "approved/GRAS as an ingredient" status is about additive safety, not proven fat-loss benefit.

Why is it still sold? Because it's marketed as an unregulated "research" peptide, which doesn't require the proof a real medicine does — and "fat-burning, no side effects" is an easy sell.

Key takeaway

AOD-9604 is a tidy idea — keep growth hormone's fat-burning, lose its side effects — with encouraging mouse data behind it. But it was actually tested in people, and it underperformed: only a small weight change, no dose-response, and a shelved development programme. Set against the GLP-1 drugs that genuinely work, its human evidence is thin. Interesting mechanism, unconvincing results, no approval — not the fat-loss shortcut it's sold as.